Related Experiment Video
Updated: May 31, 2026
11:19
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
Camilla Pilati1, Mohamed Amessou, Michel P Bihl
1Génomique fonctionnelle des tumeurs solides, Institut National de la Santé et de la Recherche Médicale (Inserm), U674, Paris, F-75010, France.
The Journal of Experimental Medicine
|June 22, 2011
Summary
New research identifies somatic signal transducer and activator of transcription 3 (STAT3) mutations in inflammatory hepatocellular adenomas (IHCAs). These STAT3 mutations activate interleukin-6 (IL-6) signaling, revealing a novel mechanism in benign liver tumor development.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumors.
- Interleukin-6 (IL-6) signaling, mediated by IL-6 signal transducer (IL6ST; gp130), is implicated in 60% of IHCAs.
- A subset of IHCAs lacks IL6ST mutations, suggesting alternative oncogenic pathways.
Purpose of the Study:
- To investigate the role of signal transducer and activator of transcription 3 (STAT3) mutations in IHCAs lacking IL6ST mutations.
- To elucidate the mechanism by which STAT3 mutations contribute to IHCA development.
- To identify novel therapeutic targets in benign liver tumorigenesis.
Main Methods:
- Analysis of IHCA tumor samples for somatic STAT3 mutations.
- Characterization of IHCA-derived STAT3 mutants in hepatocellular cells.
- Assessment of IL-6 signaling pathway activation and STAT3 dimerization.
- Investigation of the role of tyrosine kinases JAK1 and Src in STAT3 activation.
Main Results:
- Somatic STAT3 mutations were identified in 12% (6/49) of IHCAs without IL6ST mutations.
- Mutations were predominantly in the STAT3 SH2 domain, promoting constitutive dimerization and IL-6 pathway activation.
- IHCA STAT3 mutants exhibited ligand-independent activation and hypersensitivity to IL-6, with increased phosphorylation at tyrosine 705.
- Inhibition of JAK1 or Src kinases reduced the constitutive activity of IHCA STAT3 mutants.
Conclusions:
- Somatic STAT3 mutations represent a novel mechanism of IL-6 pathway activation in a subset of IHCAs.
- These findings highlight the critical role of the IL-6-STAT3 pathway in benign hepatocellular tumorigenesis.
- STAT3 mutations may serve as potential therapeutic targets for specific IHCA subtypes.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...